Artificial Intelligence in Mass Spectrometry-Based Metabolomics and Lipidomics for Drug Discovery and Development

Artificial intelligence applied to mass spectrometry-based metabolomics and lipidomics has advanced through three technological generations: chemometric and classical machine learning, deep learning, and self-supervised foundation models, with large language models so far entering mainly at the edges. The metabolome and lipidome lie closest to drug action, yet they have been among the slowest omics layers to adopt modern artificial intelligence. This paradox arises from their downstream position, which leaves them without a closed molecular reference and without the standardized, readily modeled data available to the genome and transcriptome. This review examines what these methods contribute to drug discovery and development. We survey applications across the drug-development pipeline, from target identification and mechanism-of-action deconvolution, through the prediction of drug-induced toxicity, to pharmacometabolomics, in which pre-dose metabolic phenotypes inform patient stratification and dosing. Across these metabolomic and lipidomic applications, interpretable classical machine learning remains the dominant form of artificial intelligence. The newer deep-learning and foundation models have concentrated instead on compound annotation, the cross-cutting problem of assigning confident identities to spectra, yet successive generations have mitigated but not solved it. Beyond annotation confidence, batch effects, semi-quantification, and small-cohort overfitting also remain practical constraints. Overall, targeted, hypothesis-driven metabolomic and lipidomic studies can already support drug discovery when their inferences are restricted to confidently identified metabolites, whereas open, hypothesis-free discovery remains the frontier. Near-term progress will depend less on any single algorithm than on curated spectral resources, rigorous measurement, leakage-aware validation, and honest reporting of identification confidence.

Authors

Institutions

Publication Details

Journal
Biomolecules & Therapeutics
Published
2026-10-08
DOI
https://doi.org/10.4062/biomolther.2026.225
Primary Topic
Metabolomics and Mass Spectrometry Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Artificial Intelligence in Mass Spectrometry-Based Metabolomics and Lipidomics for Drug Discovery and Development

Young Jin Min, Young Cheol Yoon, Cheol Woon Jung, Sun Jo Kim et al.
Biomolecules & Therapeutics
Metabolomics and Mass Spectrometry Studies
article

Artificial Intelligence in Mass Spectrometry-Based Metabolomics and Lipidomics for Drug Discovery and Development

Young Jin Min, Young Cheol Yoon, Cheol Woon Jung, Sun Jo Kim, Hendra Mahakam Putra, Sung Won Oh, Seoyeon Choi
article en

Abstract

Artificial intelligence applied to mass spectrometry-based metabolomics and lipidomics has advanced through three technological generations: chemometric and classical machine learning, deep learning, and self-supervised foundation models, with large language models so far entering mainly at the edges. The metabolome and lipidome lie closest to drug action, yet they have been among the slowest omics layers to adopt modern artificial intelligence. This paradox arises from their downstream position, which leaves them without a closed molecular reference and without the standardized, readily modeled data available to the genome and transcriptome. This review examines what these methods contribute to drug discovery and development. We survey applications across the drug-development pipeline, from target identification and mechanism-of-action deconvolution, through the prediction of drug-induced toxicity, to pharmacometabolomics, in which pre-dose metabolic phenotypes inform patient stratification and dosing. Across these metabolomic and lipidomic applications, interpretable classical machine learning remains the dominant form of artificial intelligence. The newer deep-learning and foundation models have concentrated instead on compound annotation, the cross-cutting problem of assigning confident identities to spectra, yet successive generations have mitigated but not solved it. Beyond annotation confidence, batch effects, semi-quantification, and small-cohort overfitting also remain practical constraints. Overall, targeted, hypothesis-driven metabolomic and lipidomic studies can already support drug discovery when their inferences are restricted to confidently identified metabolites, whereas open, hypothesis-free discovery remains the frontier. Near-term progress will depend less on any single algorithm than on curated spectral resources, rigorous measurement, leakage-aware validation, and honest reporting of identification confidence.

Biomolecules & Therapeutics
Chonnam National University (KR), Seoul National University (KR), National Forensic Institute (KR)
Openalex Percentile: Top 22%
Metabolomics and Mass Spectrometry Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.